This company profile is not publicly available
|AstraZeneca Pty Ltd|
|AstraZeneca Pty Ltd|
In 2019, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of A.
[Source 2019][More on Climate Change]
In 2019, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of A.
[Source 2019][More on Human Rights]
This company received an S&P Global ESG Score of 81/100 in the Pharmaceuticals category of the 2019 SAM Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices. The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
[Source 2019][More on Sustainability Reporting]
Signatory to the Australian Packaging Covenant, a voluntary agreement to encourage waste minimisation.
[Source 2020][More on Packaging]
The 2020 Global 100 Most Sustainable Corporations in the World list is an extensive data-driven corporate sustainability assessment. The ranked companies are leaders in the field of a sustainable business approach. The efficiency of a company's energy, water, CO2 and waste management is measured in relation to its total sales volume. The disclosure of that information is a pre-condition for the assessment. Of the 123 companies in its peer group, this company ranked #2.
[Source 2020][More on Sustainability Reporting]
In 2011, the AstraZeneca reached a record $68.6 million settlement with the attorneys general of 37 US states over allegations that it improperly marketed an antipsychotic drug, Seroquel. The company also has lawsuits pending over it's drug Crestor.
[Source 2012][More on Irresponsible marketing]
This company had 3 class action injury suits settled in 2015 -
1. February 2015 - it was found liable for promoting Nexium as more effective in treating acid reflux than its cheaper and nearly identical sister drug Prilosec. The litigation for this claim last 10 years and came to an end with a US$20m settlement.
2. February 2015 - the US Department of Justice announced that this company would pay to resolve allegations of fault in an alleged Nexium kickback conspiracy. The company was responsible for a US$7.9m settlement.
3. June 2015 - Teva Pharmaceuticals settled for US$24m after being accused of keeping generic versions of Nexium off the market in a pay-for delay scheme.
[Source 2015][More on Irresponsible Marketing]
On 6 December, 2012 the European Court of Justice upheld a 53m Euro fine against this company that penalised it for policies aimed at delaying generic competition. Europe's highest court rejected appeals against rulings from AstraZeneca that it had abused its dominant position on its anti stomach acid drug Losec, bringing to a close a series of appeals since the company was first fined 60m Euros in 2005.
[Source 2012][More on Finance]
According to the democracyforsale.net website, this company donated $39,335 to Australia's major political parties between 2012 and 2018, as disclosed to the Australian Electoral Commision (AEC).
[Source 2018][More on Politics]
This company has been criticised by ActionAid for having subsidiaries in tax havens. One of the main reasons companies have subsidiaries in tax havens is to dodge their taxes. Developing countries lose more to tax dodging than they receive in aid each year.
[Source 2011][More on Finance]
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target; commit to 100% renewable power; report climate change information in mainstream reports as a fiduciary duty.
[Source 2017][More on Climate Change]
The Female FTSE Board Report 2015 examines the percentage of women on the UK's FTSE 100 boards of directors. This company was one of 41 in the FTSE 100 with at least 25% female directors.
[Source 2015][More on Workers Rights]
This company appears on the 2020 Bloomberg Gender-Equality Index, signifying a commitment to supporting gender equality through policy development, representation, and transparency.
[Source 2020][More on Human Rights]
This company received the ninth highest score in the Access to Medicine Index 2018, a ranking of the world's largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
[Source 2018][More on Human Rights]
This company received a score of 54.2/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2017][More on Sustainability Reporting]
The Corporate Research Project's Corporate Rap Sheets are dossiers summarising the most significant crimes, violations and other questionable activities of the world's largest and most controversial companies. Follow link to see this company's Corporate Rap Sheet.
|No company details currently available for AstraZeneca Pty Ltd
|No company contact details currently available for AstraZeneca Pty Ltd